Elekta (EKTAY) Stock Price, News & Analysis

Company Overview

Elekta is a global medical technology company headquartered in Stockholm, Sweden, specializing in precision radiotherapy, radiosurgery and related software for the treatment of cancer and brain disorders. Through its research and development efforts, the company designs and manufactures advanced equipment and solutions that support clinicians in delivering targeted radiation treatments while minimizing damage to healthy tissue. Elekta’s offerings span hardware, software and services, addressing the full continuum of radiation oncology care.

Key products include linear accelerators for external beam radiation therapy, such as the Versa HD and Unity MR-linac systems, as well as Gamma Knife® platforms for stereotactic radiosurgery. The company also provides brachytherapy afterloaders and applicators for internal radiation treatments. Complementing its hardware portfolio, Elekta develops treatment planning and oncology informatics software that streamline workflow, enhance treatment accuracy and facilitate collaborative care across multidisciplinary teams.

Founded in 1972 by neurosurgeon Lars Leksell, Elekta has a long heritage in developing cutting-edge radiosurgery techniques and equipment. Over the decades, the company has pioneered innovations such as stereotactic radiosurgery and intensity-modulated radiation therapy, contributing to advances in patient outcomes and treatment precision. Elekta’s commitment to research is evidenced by partnerships with leading academic and clinical institutions worldwide.

Today, Elekta serves healthcare providers in more than 120 countries through a network of direct operations and authorized distributors. The company’s leadership team, headed by President and Chief Executive Officer Gustaf Salford, emphasizes strategic investments in technology, training and support services to ensure customers can maximize the value of their treatment platforms. By combining scientific expertise with global reach, Elekta continues to shape the future of radiation therapy and improve quality of life for patients around the world.

Key Stats

• Today's Range: $5.16 to $5.19
• 50-Day Range: $4.85 to $5.49
• 52-Week Range: $4.36 to $7.13
• Volume: 3,536 shs
• Average Volume: 6,732 shs
• Market Capitalization: $1.99 billion
• P/E Ratio: 103.82
• Dividend Yield: 2.31%
• Price Target: N/A
• Consensus Rating: Hold

Elekta Stock Analysis - MarketRank™

Elekta scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Elekta.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 19.44%

Earnings Growth

Earnings for Elekta are expected to grow by 19.44% in the coming year, from $0.36 to $0.43 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elekta is 103.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.05.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elekta is 103.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 19.96.

Price to Book Value per Share Ratio

Elekta has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Elekta has been sold short.

Short Interest Ratio / Days to Cover

Elekta has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elekta has recently decreased by 99.51%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Elekta pays a meaningful dividend of 2.29%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Elekta does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Elekta is 240.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Elekta will have a dividend payout ratio of 27.91% next year. This indicates that Elekta will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Elekta has been sold short.

Short Interest Ratio / Days to Cover

Elekta has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elekta has recently decreased by 99.51%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

Elekta has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Elekta this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elekta insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.28% of the stock of Elekta is held by insiders. A high percentage of insider ownership can be a sign of company health.

EKTAY Stock Analysis - Frequently Asked Questions

How have EKTAY shares performed this year?

Elekta's stock was trading at $5.66 at the beginning of 2025. Since then, EKTAY stock has decreased by 8.3% and is now trading at $5.19.

How were Elekta's earnings last quarter?

Elekta AB (OTCMKTS:EKTAY) released its earnings results on Wednesday, May, 28th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.13 by $0.02. The company had revenue of $503.22 million for the quarter, compared to analysts' expectations of $507.19 million. Elekta had a net margin of 1.15% and a trailing twelve-month return on equity of 11.55%.

How do I buy shares of Elekta?

Shares of EKTAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/28/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/27/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EKTAY
• CIK: 1451160
• Web: www.elekta.com
• Phone: (685) 872-5400
• Fax: 46-8-587-255-00
• Employees: 4,718
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.05
• Trailing P/E Ratio: 103.82
• Forward P/E Ratio: 14.42
• P/E Growth: N/A
• Net Income: $22.37 million
• Net Margins: 1.15%
• Pretax Margin: 2.72%
• Return on Equity: 11.55%
• Return on Assets: 3.75%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 1.09
• Quick Ratio: 0.86

Sales & Book Value

• Annual Sales: $1.71 billion
• Price / Sales: 1.17
• Cash Flow: $0.61 per share
• Price / Cash Flow: 8.48
• Book Value: $2.19 per share
• Price / Book: 2.37

Miscellaneous

• Outstanding Shares: 383,570,000
• Free Float: 225,231,000
• Market Cap: $1.99 billion
• Optionable: Not Optionable
• Beta: 1.20